Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
This article was originally published in The Tan Sheet
Executive Summary
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
You may also be interested in...
ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD
ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD
ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD